Skip to main content
. 2012 Feb 22;37(6):1444–1454. doi: 10.1038/npp.2011.330

Figure 2.

Figure 2

Symptom dimensions as assessed by the Montgomery–Asberg Depression Rating Scale in patients with hepatitis C receiving IFN-α/ribavirin therapy and undergoing double-blind, placebo-controlled treatment (mean with bars indicating standard error). (a) Depressive symptom dimension. (b) Anxious symptom dimension. (c) Cognitive symptom dimension. (d) Neurovegetative symptom dimension.